CN102657744B - Medicament for treating mastitis - Google Patents
Medicament for treating mastitis Download PDFInfo
- Publication number
- CN102657744B CN102657744B CN 201210075568 CN201210075568A CN102657744B CN 102657744 B CN102657744 B CN 102657744B CN 201210075568 CN201210075568 CN 201210075568 CN 201210075568 A CN201210075568 A CN 201210075568A CN 102657744 B CN102657744 B CN 102657744B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicament
- mastitis
- herba
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 208000004396 mastitis Diseases 0.000 title claims abstract description 12
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims abstract description 5
- 229940097275 indigo Drugs 0.000 claims abstract description 5
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims abstract description 5
- 241000717739 Boswellia sacra Species 0.000 claims description 5
- 241000628997 Flos Species 0.000 claims description 5
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 5
- 241000180649 Panax notoginseng Species 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 241000220433 Albizia Species 0.000 claims description 4
- 235000011438 Albizia odoratissima Nutrition 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 241000405217 Viola <butterfly> Species 0.000 claims description 2
- 239000004863 Frankincense Substances 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 240000007185 Albizia julibrissin Species 0.000 abstract 1
- 235000011468 Albizia julibrissin Nutrition 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- NEZONWMXZKDMKF-SNVBAGLBSA-N Shikonin Chemical compound C1=CC(O)=C2C(=O)C([C@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-SNVBAGLBSA-N 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 244000178320 Vaccaria pyramidata Species 0.000 abstract 1
- 235000010587 Vaccaria pyramidata Nutrition 0.000 abstract 1
- 244000137773 Viola philippica Species 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 206010060891 General symptom Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- -1 absorption carrier Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 206010037294 Puerperal pyrexia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000019989 milk ejection Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicament for treating mastitis. The medicament is prepared from the following raw materials by weight: cowherb 3-8 parts, natural indigo 4-8 parts, Chinese angelica 3-6 parts, silktree flower 2-5 parts, wolfberry 3-6 parts, tokyo violet herb 1-10 parts, pseudo-ginseng 3-6 parts, Ligusticum wallichii 2-6 parts, dandelion 1-4 parts, licorice 3-7 parts and frankincense 2-6 parts. The medicament provided in the invention has the advantages of simple components and low cost, and has an obvious treatment effect for mastitis.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of medicament for the treatment of mastitis.
Background technology
Mastitis refer to that the acute festering type of mammary gland infects, and are the puerperal commonly encountered diseases, are one of reasons that causes puerperal fever, are most commonly in the nursing women, especially the primipara.Any time of age of sucking all can take place, and the beginning of suckling is the most common.
Summary of the invention
The purpose of this invention is to provide a kind of medicament for the treatment of mastitis.
In order to realize purpose of the present invention, the invention provides a kind of medicament for the treatment of mastitis, it is to be made by following materials by weight: 2～6 parts of Semen Vaccariae 3-8 part, 4～8 parts of Indigo Naturaliss, 3～6 parts of Radix Angelicae Sinensis, 2～5 parts of Flos Albiziaes, 3～6 parts of Fructus Lycii, 1～10 part of Herba Violae, 3～6 parts of Radix Notoginseng, 2～6 parts of Rhizoma Chuanxiongs, 1～4 part of Herba Taraxaci, 3～7 parts in Radix Glycyrrhizae and Olibanums.
Preferably, the powder for the treatment of mastitis of the present invention is to be made by following materials by weight: 4 parts of 5 parts of Semen Vaccariae, 6 parts of Indigo Naturaliss, 5 parts of Radix Angelicae Sinensis, 4 parts of Flos Albiziaes, 4 parts of Fructus Lycii, 5 parts of Herba Violaes, 6 parts of Radix Notoginseng, 4 parts of Rhizoma Chuanxiongs, 2 parts of Herba Taraxacis, 6 parts in Radix Glycyrrhizae and Olibanums.
Preferably, described medicament can be made tablet, dispersible tablet, powder or capsule.Can adopt method well known to those skilled in the art to carry out medicaments preparation.As required, can add various pharmaceutically acceptable carriers.Described carrier comprises diluent, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier, lubricant of pharmaceutical field routine etc.Medicament of the present invention in the preparation, selectable filler has: starch, Icing Sugar, calcium phosphate, dextrin, microcrystalline Cellulose, lactose, pregelatinized Starch, mannitol etc.; Selectable binding agent has: sodium carboxymethyl cellulose, PVP-K30, hydroxypropyl cellulose, starch slurry, methylcellulose, ethyl cellulose, hydroxypropyl emthylcellulose, gelling starch etc.; Selectable disintegrating agent has: dried starch, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose etc.; Selectable lubricant has: magnesium stearate, Pulvis Talci, sodium lauryl sulphate, micropowder silica gel etc.
Component of the present invention is simple, with low cost, for mastitis apparent in view therapeutic effect is arranged.
The specific embodiment
Further specify the present invention below by embodiment.It should be understood that embodiments of the invention are for explanation the present invention rather than limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.
The preparation of embodiment 1 powder
Take by weighing Semen Vaccariae 50 grams, Indigo Naturalis 60 grams, Radix Angelicae Sinensis 50 grams, Flos Albiziae 40 grams, Fructus Lycii 40 grams, Herba Violae 50 grams, Radix Notoginseng 60 grams, Rhizoma Chuanxiong 40 grams, Herba Taraxaci 20 grams, Radix Glycyrrhizae 60 grams and Olibanum 40 grams and fully mix, pulverize, cross 80 mesh sieves.Take by weighing Icing Sugar 130 grams then, cross 80 mesh sieves and above-mentioned raw materials and mix, namely.Gained powder is divided into 100 bags.
Experimental example
Diagnostic criteria
Diagnostic criteria is formulated with reference to " disease of tcm diagnosis criterion of therapeutical effect ": in (1) initial stage breast the carbuncle lump is arranged, skin is not red or little red, and milk ejection is not smooth; (2) can be with heating, aversion to cold, headache etc.; (3) blood leukocytes sum or neutrophilic granulocyte number increase.Confirm not form mammary abscess person through color ultrasound examination.
Choose patient's 50 examples that meet above-mentioned standard, 21～35 years old age, average out to 28 years old.All be women breast-feeding their children, course of disease 1-4d.
Use the powder of the present invention of embodiment 1 preparation to treat, every day twice, each 1 bag, 3 days is a course for the treatment of.
Diagnostic criteria
(1) cure: General Symptoms disappears, and lump dissipates; (2) take a turn for the better: General Symptoms disappears, and local pain alleviates; (3) do not heal: symptom does not have improvement or increases the weight of, and forms mammary abscess.
Through the treatment of a course for the treatment of, all the patient all meets the standard of healing.And in therapeutic process, do not see obvious adverse reaction.
Claims (2)
1. medicament for the treatment of mastitis, it is characterized in that it is to be made by following materials by weight: 2～6 parts of Semen Vaccariae 3-8 part, 4～8 parts of Indigo Naturaliss, 3～6 parts of Radix Angelicae Sinensis, 2～5 parts of Flos Albiziaes, 3～6 parts of Fructus Lycii, 1～10 part of Herba Violae, 3～6 parts of Radix Notoginseng, 2～6 parts of Rhizoma Chuanxiongs, 1～4 part of Herba Taraxaci, 3～7 parts in Radix Glycyrrhizae and Olibanums.
2. the medicament for the treatment of mastitis according to claim 1, it is characterized in that it is to be made by following materials by weight: 4 parts of 5 parts of Semen Vaccariae, 6 parts of Indigo Naturaliss, 5 parts of Radix Angelicae Sinensis, 4 parts of Flos Albiziaes, 4 parts of Fructus Lycii, 5 parts of Herba Violaes, 6 parts of Radix Notoginseng, 4 parts of Rhizoma Chuanxiongs, 2 parts of Herba Taraxacis, 6 parts in Radix Glycyrrhizae and Olibanums.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210075568 CN102657744B (en) | 2012-03-21 | 2012-03-21 | Medicament for treating mastitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210075568 CN102657744B (en) | 2012-03-21 | 2012-03-21 | Medicament for treating mastitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102657744A CN102657744A (en) | 2012-09-12 |
| CN102657744B true CN102657744B (en) | 2013-08-28 |
Family
ID=46767412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210075568 Expired - Fee Related CN102657744B (en) | 2012-03-21 | 2012-03-21 | Medicament for treating mastitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102657744B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103494964B (en) * | 2013-09-23 | 2015-01-21 | 张欣玲 | Traditional Chinese medicine composition for treating acute mastitis |
| CN104095996A (en) * | 2014-08-12 | 2014-10-15 | 王忠亮 | Medicinal composition for treating acute abscess stage mastitis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101024068A (en) * | 2006-02-19 | 2007-08-29 | 董继生 | Medicine for treating mastitis |
| CN101229357B (en) * | 2008-01-30 | 2010-12-01 | 胡永旺 | Chinese traditional medicine for treating mammary glands hyperplasia |
| CN101361894A (en) * | 2008-08-29 | 2009-02-11 | 蒋保珍 | Medicine for treating mastitis |
-
2012
- 2012-03-21 CN CN 201210075568 patent/CN102657744B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102657744A (en) | 2012-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101584797A (en) | Application of traditional Chinese medicine composition in preparing medicament for treating climacteric syndrome | |
| CN104666951A (en) | Traditional Chinese medicine composition for treating parturient paresis puerperal fever | |
| CN102657821B (en) | Drug for treating ovarian cyst | |
| CN101804105B (en) | Medicine composition for treating mammitis and preparation method thereof | |
| CN104208540B (en) | Compound traditional Chinese medicine for treating gastric cancer and preparation method thereof | |
| CN103830674B (en) | One treats lipomatous pharmaceutical composition and preparation method and purposes | |
| CN102657744B (en) | Medicament for treating mastitis | |
| CN101829315B (en) | Traditional Chinese medicine composition for treating headache during menstruation and preparation method thereof | |
| CN115282229B (en) | Traditional Chinese medicine composition for treating qi deficiency and blood stasis type coronary heart disease and preparation method thereof | |
| CN102895466A (en) | Chinese medicine for preventing miscarriages and preparation method for Chinese medicine | |
| CN104383242A (en) | Medicament composition for treating ovarian cyst and preparation method thereof | |
| CN102552511B (en) | Medicament for treating diarrhea | |
| CN102698064B (en) | Medicament for treating climacteric syndrome | |
| CN102526385B (en) | Medicament for treating climacteric syndrome | |
| CN102600359B (en) | Patch for treating abdominal wall endometriosis after cesarean section | |
| CN101108210B (en) | Medicine for treating cervical vertebra disease | |
| CN104189770A (en) | Pharmaceutical composition for treating tuberculous pleuritis and preparation method thereof | |
| CN103301368A (en) | Medicament for treating hyperactivity | |
| CN103041363B (en) | Medicament for treating mammitis | |
| CN102895580B (en) | Pulse invigorating and kidney tonifying medicament | |
| CN105998421A (en) | Traditional Chinese medicine composition for treating hysteromyoma | |
| CN101537125B (en) | Chinese medicine for treating uterine cancer | |
| CN106138555A (en) | A kind of pharmaceutical composition preventing premature ovarian failure and preparation method thereof | |
| CN106309636B (en) | Pharmaceutical composition for uterine bleeding | |
| CN105031321A (en) | Traditional Chinese medicine for treating bone tumour |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHI LAIXIN Free format text: FORMER OWNER: CHU XUEZHEN Effective date: 20141231 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 273100 JINING, SHANDONG PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141231 Address after: 226400, building 501, building 12, green garden village, dug Town, Rudong County, Jiangsu Patentee after: Shi Laixin Address before: Hospital of Obstetrics and gynecology at No. 129 Shandong city in Qufu Province, Shandong city of Qufu Province Cang Geng road 273100 Patentee before: Chu Xuezhen |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130828 Termination date: 20190321 |